Merit Medical Systems Inc

The stock has mounted a strong recovery off its mid-May lows, clearing the 200-day SMA and establishing a bullish EMA stack. After a steep rally into the 52-week high area, price is consolidating above the 20 EMA, creating a structurally favorable zone for pullback entries. Medium-term, the Stage 2 uptrend remains intact above rising EMAs, but near-term overbought signals and overhead resistance counsel patience until support around the 20 EMA is tested and absorbed.

• ↑Q2 revenue $418.8 M (up 10% YoY) topped estimates
• ↑Non-GAAP operating margin expanded to 22.6% on tighter cost controls
• ↓Profitability factors are weak, reflecting low earnings yield pressures